Publications

Notable Recent Publications

These are some recent publications which give a flavour of the research from the Barclay lab. For a complete list of publications, please see below.

Species difference in ANP32A underlies influenza A virus polymerase host restriction. Nature (2016).
Jason S. Long, Efstathios S. Giotis, Olivier Moncorgé, Rebecca Frise, Bhakti Mistry, Joe James, Mireille Morisson, Munir Iqbal, Alain Vignal, Michael A. Skinner & Wendy S. Barclay

This paper identified a key factor that explained why the polymerases from avian influenza viruses are restricted in humans.  For more, please see the associated New and Views.

See our latest ANP32 papers here: eLIFE, Journal of Virology, Journal of Virology.

The mechanism of resistance to favipiravir in influenza. PNAS (2018).
Daniel H. Goldhill, Aartjan J. W. te Velthuis, Robert A. Fletcher, Pinky Langat, Maria Zambon, Angie Lackenby & Wendy S. Barclay

This paper showed how influenza could evolve resistance to favipiravir, an antiviral that may be used to treat influenza. The residue that mutated to give resistance was highly conserved suggesting that the mechanism of resistance may be applicable to other RNA viruses.

Internal genes of a highly pathogenic H5N1 influenza virus determine high viral replication in myeloid cells and severe outcome of infection in mice. Plos Path. (2018).
Hui Li*, Konrad C. Bradley*, Jason S. Long, Rebecca Frise, Jonathan W. Ashcroft, Lorian C. Hartgroves, Holly Shelton, Spyridon Makris, Cecilia Johansson, Bin Cao & Wendy S. Barclay

Why do avian influenza viruses like H5N1 cause such severe disease in humans? This paper demonstrated that H5N1 viruses replicate better than human viruses in myeloid cells from mice leading to a cytokine storm and more severe disease.

Citation

BibTex format

@article{Dowall:2016:10.3390/v8110277,
author = {Dowall, SD and Bewley, K and Watson, RJ and Vasan, SS and Ghosh, C and Konai, MM and Gausdal, G and Lorens, JB and Long, J and Barclay, W and Garcia-Dorival, I and Hiscox, J and Bosworth, A and Taylor, I and Easterbrook, L and Pitman, J and Summers, S and Chan-Pensley, J and Funnell, S and Vipond, J and Charlton, S and Haldar, J and Hewson, R and Carroll, MW},
doi = {10.3390/v8110277},
journal = {Viruses},
title = {Antiviral Screening of Multiple Compounds against Ebola Virus},
url = {http://dx.doi.org/10.3390/v8110277},
volume = {8},
year = {2016}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - In light of the recent outbreak of Ebola virus (EBOV) disease in West Africa, there have been renewed efforts to search for effective antiviral countermeasures. A range of compounds currently available with broad antimicrobial activity have been tested for activity against EBOV. Using live EBOV, eighteen candidate compounds were screened for antiviral activity in vitro. The compounds were selected on a rational basis because their mechanisms of action suggested that they had the potential to disrupt EBOV entry, replication or exit from cells or because they had displayed some antiviral activity against EBOV in previous tests. Nine compounds caused no reduction in viral replication despite cells remaining healthy, so they were excluded from further analysis (zidovudine; didanosine; stavudine; abacavir sulphate; entecavir; JB1a; Aimspro; celgosivir; and castanospermine). A second screen of the remaining compounds and the feasibility of appropriateness for in vivo testing removed six further compounds (ouabain; omeprazole; esomeprazole; Gleevec; D-LANA-14; and Tasigna). The three most promising compounds (17-DMAG; BGB324; and NCK-8) were further screened for in vivo activity in the guinea pig model of EBOV disease. Two of the compounds, BGB324 and NCK-8, showed some effect against lethal infection in vivo at the concentrations tested, which warrants further investigation. Further, these data add to the body of knowledge on the antiviral activities of multiple compounds against EBOV and indicate that the scientific community should invest more effort into the development of novel and specific antiviral compounds to treat Ebola virus disease.
AU  - Dowall,SD
AU  - Bewley,K
AU  - Watson,RJ
AU  - Vasan,SS
AU  - Ghosh,C
AU  - Konai,MM
AU  - Gausdal,G
AU  - Lorens,JB
AU  - Long,J
AU  - Barclay,W
AU  - Garcia-Dorival,I
AU  - Hiscox,J
AU  - Bosworth,A
AU  - Taylor,I
AU  - Easterbrook,L
AU  - Pitman,J
AU  - Summers,S
AU  - Chan-Pensley,J
AU  - Funnell,S
AU  - Vipond,J
AU  - Charlton,S
AU  - Haldar,J
AU  - Hewson,R
AU  - Carroll,MW
DO  - 10.3390/v8110277
PY  - 2016///
SN  - 1999-4915
TI  - Antiviral Screening of Multiple Compounds against Ebola Virus
T2  - Viruses
UR  - http://dx.doi.org/10.3390/v8110277
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000390109100001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/49635
VL  - 8
ER  -
Download